

PUBLIC SUMMARY DOCUMENT

Product: Brava Skin Cleanser Wipes (Pack of 15 wipes)

Applicant: Coloplast Pty Ltd

Date of SPAP Meeting: 11 April 2016

1. Proposed Listing on the Stoma Appliance Scheme

The applicant, Coloplast Pty Ltd, sought listing of the Brava Skin Cleanser Wipes (pack of 15 wipes) in subgroup 9(d) of the Stoma Appliance Scheme (SAS) Schedule. The product was proposed for listing at the benchmark unit price of \$0.478 per wipe, with a maximum monthly quantity of 105 units.

2. Comparator

The applicant nominated Dansac Skin Lotion Wipes, pack of 50 wipes (SAS code 3568T), which is currently listed in subgroup 9(d), as the comparator. This product is currently listed at the unit price of \$0.478, maximum quantity of 100 units.

3. Background

This was the Stoma Product Assessment Panel (SPAP)'s first consideration of this product.

4. Clinical Place for the Product

The proposed product provides an alternative for users requiring cleanser wipes for the peristomal area.

5. SPAP Comment

Clinical Analysis

The Panel noted that the proposed product is a sting free (no alcohol) cleanser wipe. It appears to be 'no worse than' current wipes in subgroup 9(d).

Economic Analysis

Not undertaken.

Financial Analysis

Listing of this product would result in a cost compared to the comparator product in 9(d) of the SAS Schedule. It is therefore likely that there would be a budgetary impact for the SAS as a consequence of listing this product under the conditions requested by the applicant.

6. SPAP Recommendation

The SPAP recommended that the Brava Skin Cleanser Wipes, (pack of 15 wipes) be listed in subgroup 9(d) on the SAS Schedule, at a unit price of \$0.478 per wipe, with a maximum monthly quantity of 105 units.

The Panel also noted that all recommendations for products to be listed in Group 9 of the SAS Schedule may be subject to change as a result of the outcomes from the Group 9 Review.

7. Context for Decision

The SPAP helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. An SPAP decision not to recommend listing or changes to a listing does not represent a final SPAP view about the merits of a particular stoma product. A company can resubmit to the SPAP following a decision not to recommend listing or changes to a listing. The SPAP is

an advisory committee and as such its recommendations are non-binding on Government. All SPAP recommendations are subject to Cabinet/Ministerial approval.

8. Applicant's Comment

Coloplast agrees with SPAP's recommendation.